lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab servus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting mutiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versous placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing retmitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo diease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing rmitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trals examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis gremain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting mfultiple sclerosis remain inconclusive
lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerosis remain inconclusive|lack high quality randomised control trials examining rituximab versus placebo disease-modifying therapies benefits rituximab relapsing remitting multiple sclerostis remain inconclusive
